Navigation Links
Oticon Tapes Out Innovative Hearing-Aid DSP Using Synopsys IC Compiler
Date:6/2/2008

IC Compiler Enables Extremely Low-Power Design for Innovative Medical

Device

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- Synopsys, Inc. (Nasdaq: SNPS), a world leader in software and IP for semiconductor design and manufacturing, today announced that Oticon has taped out part of its next-generation digital signal processor (DSP) chipset for hearing-aid devices using Synopsys' IC Compiler design planning and place-and-route product, which is part of the Eclypse(TM) Low Power Solution. Enhanced design productivity, small form factor, and low power consumption were key requirements for Oticon's design. Oticon leveraged IC Compiler within Synopsys' Pilot Design Environment, delivering predictable low-power results and enabling faster time to tapeout.

"Battery life is one of our customers' major concerns. Taking advantage of IC Compiler's automatic multi-voltage, MTCMOS shutdown, and multi-threshold capabilities, we were able to meet our extreme low-power requirements and deliver new innovation to our hearing aid users," said Mogens Balsby, director of IC Design at Oticon. "Because we were moving to a new, advanced technology node and time-to-market was critical, we used Synopsys' Pilot tapeout-proven design environment, which includes full implementation, formal checking, and physical verification and leverages best-in-class tools. We were extremely satisfied with the results achieved with IC Compiler and the Pilot Design Environment on our complex design."

Oticon is the world leader in the design, development, and manufacture of hearing aids that embed sophisticated integrated circuits (ICs) that deliver massively parallel, digital audio signal processing and wireless communication. The new DSP's breakthrough real-time wireless technology enables two hearing aids to work together to process sound, similar to the way the brain receives input from two ears, to deliver three-dimensional auditory information that enhances the user's listening experience.

"IC Compiler's automated low-power optimization technology was instrumental in helping Oticon meet its low-power requirements, and Synopsys' Pilot Design Environment enabled them to complete their tapeout on schedule," said Antun Domic, senior vice president and general manager of Synopsys' Implementation Group. "As Oticon continues creating innovative products for their customers, it can leverage more of the advanced capabilities in IC Compiler, such as concurrent hierarchical design, for further product differentiation and faster time-to-results."

About IC Compiler

IC Compiler is Synopsys' comprehensive physical design solution. It provides superior results and faster time-to-results by extending physical synthesis to full place-and-route, and by enabling signoff-driven design closure. Older solutions have a limited horizon because placement, clock tree, and routing are separate, disjointed operations. IC Compiler's XPS technology breaks down the walls between these steps by extending physical synthesis to full place-and-route. IC Compiler has a unified, TCL-based architecture that implements innovations and harnesses some of Synopsys' best core technologies. It is a comprehensive physical design system with the features necessary to implement next-generation designs, including physical synthesis, design planning, placement, routing, timing, signal integrity (SI) optimization, power reduction, design-for-test (DFT), and yield optimization.

IC Compiler is part of the Eclypse Low Power Solution, which is a comprehensive alignment of low power design and verification technologies, IP, methodologies and services built on industry standards.

About Synopsys

Synopsys, Inc. (NASDAQ:SNPS) is a world leader in electronic design automation (EDA), supplying the global electronics market with the software, intellectual property (IP) and services used in semiconductor design and manufacturing. Synopsys' comprehensive, integrated portfolio of implementation, verification, IP, manufacturing and field-programmable gate array (FPGA) solutions helps address the key challenges designers and manufacturers face today, such as power and yield management, system-to-silicon verification and time-to-results. These technology-leading solutions help give Synopsys customers a competitive edge in bringing the best products to market quickly while reducing costs and schedule risk. Synopsys is headquartered in Mountain View, California, and has more than 60 offices located throughout North America, Europe, Japan, Asia and India. Visit Synopsys online at http://www.synopsys.com/.

Synopsys and Eclypse are registered trademarks or trademarks of Synopsys, Inc. Any other trademarks or registered trademarks mentioned in this release are the intellectual property of their respective owners.

Sheryl Gulizia

Synopsys, Inc.

650-584-8635

sgulizia@synopsys.com

Lisa Gillette-Martin

MCA, Inc.

650-968-8900 ext. 115

lgmartin@mcapr.com


'/>"/>
SOURCE Synopsys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
3. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
4. Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference
5. Riverside Partners Teams with Management to Acquire Innovative Product Achievements
6. TriWest Receives National Awards for Innovative Video Communications to Military Community
7. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
8. Innovative antennae may signal a new wave in health care provision
9. Beautiful Teeth Not Just for the Dentists Office Anymore / SpaBrite Teeth Whitening System(TM) Introduces Innovative, New Teeth Whitening Experience To Spas
10. Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend Warriors
11. In blood vessel stents, innovative materials allow better control, delivery of gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency ... Belmont, and Palo Alto, is proud to announce an important upgrade to its geographic ... for home care close to home, and by having city-specific pages, NuevaCare is answering ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a ... Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based on ... IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales process ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today ... 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical ... behavioral health analytics to improve Medicaid population health management. , ODH will also have ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... TaskMate Go. Core benefits and advantages built into the home office sit stand ... look and feel. Ability to gain the benefits embedded in the TaskMate Go ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs ... benchmarks in the global Oesophageal Cancer market. The research ... the key drugs marketed for Oesophageal Cancer and their clinical attributes? ...
Breaking Medicine Technology: